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Numerous reports have conﬁrmed that increased macrolide use in the treatment
of respiratory tract infection has contributed to the emergence of antibiotic resistance
worldwide. Studies have also shown that pneumococcal vaccine can reduce pneumo-
coccal resistance. The aim of this study was to determine the prevalence of co-
resistance to penicillin and other antibiotics in macrolide-resistant (MR) non-invasive
pneumococcal isolates and to evaluate serotype distribution in resistant strains in the
pre-vaccine era in Serbia. About 80% of MR isolates expressed the MLS phenotype
with very high resistance to both erythromycin and clindamycin. A total of 132
(84.1%) MR isolates were multiresistant, i.e., they were resistant to erythromycin,
penicillin, tetracycline, and trimethoprim–sulfamethoxazole. Among 157 MR pneu-
mococci, 11 different serotypes were found. Four serotypes, 19F, 14, 6B, and 23F,
accounted for 77.7% of all MR pneumococcal isolates. Among isolates with the cMLS
phenotype, serotypes 19F and 14 were predominant, whereas serotype 6A was the
most common among those with the M phenotype, followed by 14. In conclusion, co-
resistance to macrolides and penicillin in our non-invasive pneumococcal isolates is
high. The majority of tested strains (∼80%) belonged to the four serotypes (19F, 14,
6B, and 23F) that are included in all conjugate vaccine formulations.
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Introduction
Streptococcus pneumoniae (pneumococcus) is one of the most important
human pathogens. It is the most common cause of community-acquired pneumo-
nia [1–3], sinusitis, and otitis media, as well as invasive diseases, such as
bacteremia, sepsis, and meningitis. Parenteral antibiotics, such as high doses of
penicillin, third-generation cephalosporins, meropenem, vancomycin, and line-
zolid, are used for the treatment of pneumococcal invasive diseases, while
treatment for non-invasive infections typically includes oral beta-lactam antibio-
tics, macrolides, and newer generations of ﬂuoroquinolones.
In the past, beta-lactam antibiotics were widely used as initial empirical
treatment of community-acquired respiratory tract infections (CARTI), which led
to an increase in the resistance of common respiratory pathogens. Global
surveillance of resistance in bacteria causing CARTI has shown that beta-lactam
non-susceptibility rates increased worldwide during the 1990s and 2000s and
reaching the alarming level. The Alexander Project monitored resistance in
S. pneumoniae in 9-year period during 1992–2001 and reported increase of
pneumococcal non-susceptibility rate to penicillin. In some countries, such as
Spain and France, pneumococcal resistance to penicillin raised from 25% to 7%,
respectively, at the beginning of the 1990s to 30% and 35% in 2001 [4].
Consequently, macrolides were increasingly used for the treatment of respiratory
tract infections. Thereafter, a rapid worldwide increase in the prevalence of
macrolide resistance associated with an increase in macrolide consumption was
observed.
The report of European Antimicrobial Resistance Surveillance System for
2014 indicated that there is a large variation in pneumococcal macrolide resistance
rates across Europe. In northern European countries, resistance was low (5% to
<10%), whereas in Mediterranean countries, Italy, Turkey, and France, resistance
was 10% to <25% and levels reached up to 35%–40% in Malta and Romania [5].
Resistance to macrolides in S. pneumoniae is mediated by two major
mechanisms. First is target modiﬁcation caused by a ribosomal methylase encoded
by the ermB gene and associated with high level of resistance to all macrolides,
lincosamides, and streptogramin (MLS phenotype) [6, 7]. MLS resistance can be
expressed either constitutively (cMLS) or inducibly (iMLS). The second mecha-
nism is drug efﬂux, encoded by the mefA gene, which results in lower level
resistance (M phenotype) to 14- and 15-membered macrolides [8–10].
A nationwide surveillance study performed during 2009–2011 in Serbia
indicated that non-susceptibility of invasive pneumococcal strains to penicillin and
erythromycin was 34% and 36%, respectively [11]. Pneumococcal conjugate
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vaccine (PCV) was approved for introduction in Serbia’s national immunization
program, and it will be implemented during 2018. It is documented that PCV has
profound impact on the incidence of both pneumococcal invasive and non-
invasive diseases. Also, vaccines can reduce pneumococcal resistance in vacci-
nated and unvaccinated populations by reducing the carriage of antibiotic-resistant
serotypes [12]. Assessment of changes in serotype distribution and resistance
potentially related to vaccine introduction requires valid baseline values of both
serotype distribution and antimicrobial resistance.
The aim of this study was to determine the prevalence of co-resistance to
penicillin and other antibiotics in macrolide-resistant (MR) non-invasive pneu-
mococcal isolates and to evaluate serotype distribution in resistant strains in the
pre-vaccine era in Serbia.
Materials and Methods
Bacterial isolates
A total of 157 non-invasive MR isolates of S. pneumoniae from all over
Serbia were collected in 2014. The pneumococci were isolated from nasal
discharge and nasopharyngeal swabs (103), sputum, tracheal, and bronchial
aspirates (50), and middle ear ﬂuid (4) obtained from patients with symptoms
of an acute respiratory infection presumably of bacterial etiology (sinusitis, otitis
media, and pneumonia). Out of 157 strains, 111 were isolated from children (75
among ≤5 years old) and 46 from adults (23 from persons ≥65 years old). After
isolation and identiﬁcation by conventional microbial techniques in regional
microbiology laboratories, strains were sent into the National Reference Labora-
tory for further characterization. Strain identiﬁcation was conﬁrmed in our
laboratory by optochin test, latex agglutination with the Slidex pneumo-kit
(bioMérieux, France), bile solubility test, and PCR for the lytA gene. Serotyping
was done by the capsular swelling test (Quellung reaction) using pool antisera and
factor/type antisera (Statens Serum Institut, Copenhagen, Denmark).
Antibiotic susceptibility testing
Antibiotic susceptibility testing for oxacillin, erythromycin, chlorampheni-
col, trimethoprim-sulfamethoxazole, and tetracyclines was carried out by the disk
diffusion method using disks (Bio-Rad, USA) on Mueller–Hinton agar with 5%
deﬁbrinated horse blood and 20 mg/L β-nicotinamide adenine dinucleotide
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(bioMérieux) according to the recommendations of European Committee on
Antimicrobial Susceptibility Testing (EUCAST) [13]. Oxacillin susceptibility for
screening benzylpenicillin resistance was interpreted using the recommended
current EUCAST clinical breakpoints (≥20 mm) [13]. Oxacillin-resistant isolates
were further tested for penicillin susceptibility using E-test strips (bioMérieux).
The minimum inhibitory concentrations (MICs) of penicillin were interpreted
according to the EUCAST guidelines for infections other than meningitis
(S≤0.06 μg/ml; R>2 μg/ml). Intermediate and resistant isolates were collectively
grouped as non-susceptible.
Macrolide resistance phenotypes
Macrolide resistance phenotypes were determined by a double disk diffu-
sion test using erythromycin (15 μg) and clindamycin (2 μg) disks (Bio-Rad), as
described previously [14]. The absence of an inhibition zone around both disks
suggested cross-resistance to macrolides–lincosamides–streptogramin B (cMLS
phenotype). Blunting of the clindamycin inhibition zone proximal to the erythro-
mycin disk indicated inducible resistance (iMLS). Susceptibility to clindamycin
with resistance to erythromycin suggested the M phenotype [15]. MICs of
erythromycin and clindamycin were determined using E-test strips (bioMérieux).
Statistical analysis
Data were analyzed by descriptive statistic methods and the insigniﬁcance of
the prevalence of MLS and M phenotype between children and adults was
assessed using χ2 test.
Results
The great majority (80.9%) of MR strains of S. pneumoniae tested in this
study expressed MLS phenotype (Table I). Overall, 123 of 157 isolates had a
cMLS phenotype with very high resistance to both erythromycin and clindamycin
(MICs≥256 μg/ml). Only four strains had iMLS phenotype with heterogeneous
MICs values of erythromycin and clindamycin. Therefore, MIC50 and MIC90
values in iMLS group of isolates could not be calculated. Approximately, one ﬁfth
of isolates showed the M phenotype with MIC values of erythromycin that did not
exceed 12 μg/ml. These strains were completely susceptible to clindamycin
(Table I). There was no signiﬁcant difference in the prevalence of MLS phenotype
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in children and adults, but M phenotype was signiﬁcantly more common in adults
than in children (χ2= 19.08, p< 0.01).
Oxacillin resistance was observed in 130 (82.8%) of MR pneumococcal
strains. However, according to MIC values determined by E-test, 100 of oxacillin-
resistant isolates were non-susceptible to penicillin, having MIC> 0.06 μg/ml.
Therefore, penicillin non-susceptibility was found in 63.7% of MR pneumococcal
isolates. Among them, 10 strains were resistant to penicillin, having MIC> 2 μg/ml,
whereas 90 (57.3%) strains showed intermediate resistance. In total, 57 (36.3%) of
MR pneumococcal strains were penicillin susceptible. The MIC range of penicillin
for tested strains was 0.032–16 μg/ml.
About 80% and 70% of MR non-invasive pneumococci were resistant to
tetracyclines and trimethoprim–sulfamethoxazole, respectively. Chloramphenicol
remains relatively active with susceptibility rate of 77% (Table II).
A total of 132 (84.1%) MR isolates were multiresistant, i.e., they were
resistant to three or more different antimicrobial classes: erythromycin, penicillin,
tetracycline, and trimethoprim–sulfamethoxazole. The most frequently occurring
phenotype included resistance to erythromycin, tetracyclines, and trimethoprim–
sulfamethoxazole was found in 96 (61.1%) strains.
Among 157 MR pneumococci, 11 different serotypes were found, while
four (2.5%) strains were non-typable (Table III). Four serotypes, 19F (n= 51),
Table I. Macrolide resistance phenotypes among pneumococcal isolates
MIC (μg/ml)
Phenotype Number Percentage (%) Antibiotics MIC50 MIC90 Range
M 30 19.12 Erythromycin 3 8 1.5–12
Clindamycin 0.047 0.094 0.032–0.094
iMLS 4 2.54 Erythromycin – – 4 to ≥256
Clindamycin – – 0.125 to ≥256
cMLS 123 78.34 Erythromycin ≥256 ≥256 ≥256
Clindamycin ≥256 ≥256 ≥256
Note: MIC: minimum inhibitory concentration; MLS: macrolides, lincosamides, and streptogramin; iMLS:
inducible MLS; cMLS: constitutive MLS.
Table II. Susceptibility of macrolide-resistant S. pneumoniae strains to other antibiotics
Antibiotics Resistant (%) Intermediate (%) Susceptible (%) Total (%)
Penicillin 10 (6.4) 90 (57.3) 57 (36.3) 157 (100)
Tetracycline 124 (79) 0 (0) 33 (21) 157 (100)
Chloramphenicol 36 (23) 0 (0) 121 (77) 157 (100)
Trimethoprim–sulfamethoxazole 105 (67) 8 (5) 44 (28) 157 (100)
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14 (n= 39), 6B (n= 17), and 23F (n= 15) accounted for 77.7% of all MR
pneumococcal isolates. Among isolates with the cMLS phenotype, serotypes
19F [48/123 (39.0%)] and 14 [33/123 (26.8%)] were predominant, whereas serotype
6A was the most common among those with the M phenotype [9/30 (30.0%)],
followed by 14 [6/30 (20.0%)]. Interestingly, all iMLS (n= 4) belonged to 6A
serotype. The leading serotypes 19F, 14, and 6B were signiﬁcantly more common in
children than in adults (p< 0.05). Serotypes 8, 15B, and 23A were recovered only
from adults.
Co-resistance to penicillin and erythromycin was predominantly found in
MR isolates with 19F serotype.
According to European Medical Agency, there is sufﬁcient evidence that
PCV10 provides protection against cross-reactive serotype 19A [16]. Therefore,
we calculated the PCV10 coverage with and without serotype 19A. Coverage with
PCV10 for all MR pneumococci was 77.7% (increasing to 83.4% if 19A is
included), whereas coverage with PCV13 was 92.9%. For pediatric isolates only,
coverage for PCV10 was 88.3% (92.8% if 19A is included) and 98.2% for PVC13.
Discussion
In this study, we characterized the MR population of non-invasive respira-
tory tract pneumococcal isolates in Serbia. Among MR pneumococcal population,
Table III. Distribution of serotypes among different macrolide resistance phenotypic categories of
157 macrolide-resistant S. pneumoniae isolates
Serotypes
cMLS
[n (%)]
iMLS
[n (%)]
M
[n (%)]
Children
[n (%)]
Adults
[n (%)]
Total
[n (%)]
19F 48 (39.0) 0 3 (10.0) 43 (84.3) 8 (15.7) 51 (32.5)
14 33 (26.8) 0 6 (20.0) 33 (84.6) 6 (15.4) 39 (24.8)
6B 15 (12.2) 0 2 (6.7) 12 (70.6) 5 (12.4) 17 (10.8)
23F 12 (9.8) 0 3 (10.0) 10 (66.7) 5 (33.3) 15 (9.6)
6A 2 (1.6) 0 9 (30.0) 5 (45.5) 6 (54.5) 11 (7.0)
19A 5 (4.1) 4 (100) 0 5 (55.5) 4 (44.5) 9 (5.7)
3 1 (0.8) 0 3 (10.0) 1 (25.0) 3 (75.0) 4 (2.5)
11A 2 (1.6) 0 1 (3.3) 1 (33.3) 2 (66.7) 3 (1.9)
15B 1 (0.8) 0 1 (3.3) 0 (0) 2 (100) 2 (1.3)
8 1 (0.8) 0 0 0 (0) 1 (100) 1 (0.7)
23A 1 (0.8) 0 0 0 (0) 1 (100) 1 (0.7)
Non-typable 2 (1.6) 0 2 (6.7) 1 (25.0) 3 (75.0) 4 (2.5)
Total 123 (100) 4 (100) 30 (100) 111 (100) 46 (100) 157 (100)
Note: MLS: macrolides, lincosamides, and streptogramin; iMLS: inducible MLS; cMLS: constitutive MLS.
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constitutive MLS phenotype predominated. More than 80% of isolates belonged to
this phenotype, which is characterized by cross-resistance to all three classes of
antibiotics – macrolides, lincosamides, and streptogramins – with extremely high
MIC values (≥256 μg/ml). Only four isolates expressed inducible MLS pheno-
type, which is associated with susceptibility to clindamycin without induction,
turning to high-level resistance after induction. M phenotype characterized by
low-level erythromycin resistance and susceptibility to clindamycin was detected
in almost 20% of our isolates. This phenotype was signiﬁcantly more common in
adults, whereas highly resistant MLS phenotype was equally distributed among
isolates from children and adults.
Globally, cMLS is the most prevalent resistance phenotype among MR
S. pneumoniae and it was more common than M phenotype. The high prevalence
of ermB genotype, which mostly correlated with the cMLS phenotype, was
registered in Belgium (91%), France (90%), Spain (88%), Hungary (82%), Poland
(88%), Italy (56%), and Japan (58%) [17–20]. By contrast, the M phenotype
predominates in USA [21], Canada [22], Greece [23], Ireland, and UK [19].
A high rate of macrolide resistance among invasive pneumococci in Serbia
(41%) was previously described by Gajic et al. [11] with domination of highly
resistant cMLS. It is well documented that the total macrolide use, especially long-
lasting antibiotics, such as azithromycin, is associated with increased macrolide
resistance in S. pneumoniae [24]. In Eastern Europe, in 2011, the highest
macrolide consumption was noted in Montenegro and Serbia [25]. Therefore, it
is not surprising that resistance to these drugs in S. pneumoniae in Serbia reaches
alarmingly high rates.
The prevalence of dual penicillin and macrolide non-susceptibility in Serbian
non-invasive isolates was very high (63.7%). However, a great majority of
penicillin non-susceptible pneumococci were in the intermediate category, while
6.4% were highly resistant. The rate of penicillin and macrolide co-resistance of
non-invasive pneumococcal isolates observed in this study was signiﬁcantly higher
compared to reports from Norway (1.7%) [26], the Netherlands (2.7%) [27], Czech
Republic (3%) [28], and Estonia (6%) [29], even before the widespread use of PCV
vaccination. Countries with high co-resistance rates were Greece (34.7%) [30],
Poland (39.2%) [31], and Romania (83%) [32]. As the decrease of resistance to
both penicillin and macrolides was reported due to the PCV vaccination [33, 34],
we might anticipate these changes in Serbia as well in the future.
High percentage of our erythromycin non-susceptible isolates expressed
concomitant resistance to tetracycline (∼80%) and/or trimethoprim–sulfamethoxazole
(∼70%). These patterns of resistance are widespread not only in other countries
(UK and Far East) [35, 36], but also in our close proximity (Bulgaria) [37].
Typically, erm and tetracycline resistance genes are carried on the same
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transposon [38]. Therefore, we can assume that the high prevalence (∼80%) of
macrolide and tetracycline resistance in our isolates might be due to the insertion
of transposons of the Tn916 family, but future studies should address this issue.
Eight different serotypes (19F, 14, 6B, 23F, 6A, 19A, 3, and 11A) were
found among MR pneumococci in both populations and three more (15B, 8, and
23A) only in adult group. Serotypes 19F, 14, 6B, and 23F, which are included in
both PCV10 and PCV13, accounted for almost 80% of all MR pneumococcal
isolates. The leading serotypes 19F, 14, and 6B were signiﬁcantly more common
in children than in adults. It is well described that antibiotic resistance, which may
provide a survival advantage, is associated with speciﬁc pneumococcal serotypes –
6B, 6A, 9V, 14, 19F, and 23F in the pre-vaccine era. These are predominant
carriage serotypes that colonize nasopharynx of children [5]. The serotype
epidemiology of MR non-invasive pneumococcal isolates in our country corre-
sponds to distribution of pediatric serotypes in European countries in the pre-
vaccination period [5].
The PCV has been shown to exert a profound inﬂuence on the incidence of
invasive pneumococcal diseases, epidemiology of S. pneumoniae serotypes, as
well as on the resistance. In countries with universal PCVs vaccination, vaccine
serotypes have virtually disappeared [39, 40]. Serotype coverage of both PCV10
and PCV13 of our resistant S. pneumoniae isolated from non-invasive diseases
is high (≥78%). Until 2018, both PCV10 and PCV13 vaccines were licensed
in Serbia, but vaccination was not compulsory and coverage is low. How-
ever, PCV is introduced in the new Law on Protection of Population
against Communicable Diseases and is mandatory from March 2018. Therefore,
we expect to achieve an overall reduction in pneumococcal resistance after
introduction of PCVs.
In conclusion, macrolide–penicillin co-resistance in our non-invasive pneu-
mococcal isolates is high. Four serotypes (19F, 14, 6B, and 23F) accounted for
∼80% of all strains. The prevailing pneumococcal serotypes in our country are
included in both PCV10 and PCV13 vaccine formulations indicating good
coverage. However, continuous monitoring of antimicrobial resistance and sero-
type distribution of S. pneumoniae are essential for surveillance of changes in
pneumococcal population.
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